PNEUMOCOCCAL INFECTIOUS DISEASE
Clinical trials for PNEUMOCOCCAL INFECTIOUS DISEASE explained in plain language.
Never miss a new study
Get alerted when new PNEUMOCOCCAL INFECTIOUS DISEASE trials appear
Sign up with your email to follow new studies for PNEUMOCOCCAL INFECTIOUS DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine aims to protect kids from 24 types of pneumonia
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine (RZ700) designed to protect infants and young children (ages 6 weeks to 71 months) against 24 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. The trial will check how well the vaccine triggers an immune respon…
Matched conditions: PNEUMOCOCCAL INFECTIOUS DISEASE
Phase: PHASE2 • Sponsor: Shanghai Reinovax Biologics Co.,LTD • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 10:08 UTC
-
New vaccine aims to shield kids from 24 pneumonia strains
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a new vaccine (PCV24) designed to protect children aged 2 to 23 months against 24 types of pneumococcal bacteria, which can cause pneumonia and other serious infections. About 180 healthy infants and toddlers will receive either the new vaccine or an …
Matched conditions: PNEUMOCOCCAL INFECTIOUS DISEASE
Phase: PHASE1 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 10:04 UTC
-
New vaccine aims to shield kids from 24 pneumococcal strains
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new vaccine (PCV24) that protects against 24 types of pneumococcal bacteria, which can cause serious infections like pneumonia and meningitis. About 420 healthy children aged 2 months to 5 years will receive either the new vaccine or an existing one to compare …
Matched conditions: PNEUMOCOCCAL INFECTIOUS DISEASE
Phase: PHASE2 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:06 UTC
-
New vaccine trial aims to shield 3,000+ kids from deadly pneumonia
⭐️ VACCINE ⭐️ Recruiting nowThis study tests a new 13-valent pneumococcal conjugate vaccine (PCV13) in over 3,000 healthy infants and children aged 6 weeks to 5 years. The goal is to see if the vaccine safely triggers a strong immune response against 13 types of pneumococcal bacteria, which can cause seriou…
Matched conditions: PNEUMOCOCCAL INFECTIOUS DISEASE
Phase: PHASE3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated May 08, 2026 12:04 UTC